The Nevada Cancer Research Foundation (NCRF) was established in 1983 to conduct cancer research. The NCRF main office is located in Las Vegas with satellite offices in Reno and Carson City, Nevada and Arroyo Grande, California and Port Huron, Michigan. Over 80% of the oncologists, hematologists and radiation oncologists in Nevada are investigator members of the NCRF and participate in NCI clinical trials and projects. NCRF?s primary mission is to provide quality and state-of-the-art cancer treatment in Nevada through participation in active cancer research studies for the residents of Nevada through the participation of the local physicians and health care providers. NCRF also has as part of its mission the provision of high quality, timely data to the NCI Community Oncology Research Program (NCORP) Research Bases in a research environment that sets the highest standards for the safety and welfare of the clinical trials? participants. NCRF will continue to enroll patients/participants on NCI clinical trials and plans to exceed the required annual 80 new unique patient/participant accruals evenly distributed between cancer control, prevention, and screening/post-treatment surveillance trials, and treatment and imaging trials, respectively that is required for participation in NCORP. NCRF also plans to participate in at least three cancer care delivery protocols annually and to continue to participate in bio-specimen collection for biobanks that serve as scientific resources for the NCORP Research Bases. NCRF plans to actively work with the NCI to develop an integrated community-based research network in order to reduce the cancer incidence, morbidity, and mortality in Nevada by accelerating the transfer of newly developed cancer prevention, early detection, treatment, patient management rehabilitation, quality of life, and continuing care technology. NCRF will involve NCRF staff and physicians in the scientific and educational activities of the Research Bases and will participate in studies to enhance participation of racial/ethnic and other underserved populations underrepresented in research. To accomplish these goals, the NCRF opens the program for state-wide participation, thereby providing access for participation to the residents of Nevada.

Public Health Relevance

This state-wide program (that also has 3 out-of-state affiliates) provides access to cancer research in prevention, screening, post-treatment surveillance, treatment, imaging, biospecimen collection, health-related quality of life studies, cancer control, cancer care delivery research, and cancer disparities to all interested professionals from varied medical and academic disciplines for state-wide participation, thereby providing access for participation in NCI clinical trials to Nevada residents.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Lee, Cecilia H
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Southern Nevada Cancer Research Fdn
Las Vegas
United States
Zip Code
Kyriakopoulos, Christos E; Chen, Yu-Hui; Carducci, Michael A et al. (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 36:1080-1087
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Harshman, Lauren C; Chen, Yu-Hui; Liu, Glenn et al. (2018) Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol 36:376-382
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Enzinger, Peter C; Burtness, Barbara Ann; Niedzwiecki, Donna et al. (2016) CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol 34:2736-42
Sweeney, Christopher J; Chen, Yu-Hui; Carducci, Michael et al. (2015) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 373:737-46